Journal article
The world federation of societies of biological psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: Update 2009 on the treatment of acute mania
H Grunze, E Vieta, GM Goodwin, C Bowden, RW Licht, HJ Mller, S Kasper, H Grunze, HJ Moller, H Akiskal, JL Ayuso-Gutierrez, M Bauer, P Bech, M Berk, I Bitter, G Burrows, J Calabrese, G Cassano, M Cetkovich-Bakmas, JC Cookson Show all
World Journal of Biological Psychiatry | Published : 2009
Abstract
These updated guidelines are based on a first edition that was published in 2003, and have been edited and updated with the available scientific evidence until end of 2008. Their purpose is to supply a systematic overview of all scientific evidence pertaining to the treatment of acute mania in adults. The data used for these guidelines have been extracted from a MEDLINE and EMBASE search, from the clinical trial database clinicaltrials.gov, from recent proceedings of key conferences, and from various national and international treatment guidelines. Their scientific rigor was categorised into six levels of evidence (AF). As these guidelines are intended for clinical use, the scientific eviden..
View full abstractGrants
Funding Acknowledgements
[ "Heinz Grunze received grants/research support, consulting fees and honoraria within the last 3 years from Astra Zeneca, Bial, BMS, Eli Lilly, GlaxoSmith Kline, Janssen-Cilag, Organon, Pfizer Inc, Sanofi-Aventis, Servier, UBC and UCB Belgium.", "Eduard Vieta received grants/research support, consulting fees and honoraria within the last 3 years from AstraZeneca, Bial, Bristol-Myers, Eli Lilly, Forest Research Institute, Glaxo-Smith-Kline, JanssenCilag, Jazz, Lundbeck, Merck-Sharp and Dohme, Novartis, Organon, Otsuka, Pfizer Inc, Sanofi-Aventis, Servier, and UBC.", "Siegfried Kasper received grants/research support, consulting fees and honoraria within the last 3 years from AstraZeneca, Bristol-Myers Squibb, CSC, Eli Lilly, GlaxoSmithKline, Janssen Pharmaceutica, Lundbeck, MSD, Novartis, Organon, Pierre Fabre, Pfizer, Schwabe, Sepracor, Servier, Wyeth.", "Guy Goodwin received grants/research support, consulting fees and honoraria within the last 3 years from AstraZeneca, Bristol-Myers Squibb, Eisai, Eli Lilly, Lundbeck, P1Vital, Sanofi-Aventis, Servier and Wyeth.", "Charles Bowden received grants/research support, consulting fees and honoraria within the last 3 years from Abbott Laboratories, Astra Zeneca, BristolMyers Squibb, Elan Pharmaceuticals, GlaxoSmithKline, Janssen, Lilly Research, National Institute of Mental Health, Parke Davis, Pfizer, R. W. Johnson Pharmaceutical Institute, Sanofi Synthelabo, Smith Kline Beecham, Stanley Medical Research Foundation and UCB Pharma, Inc.", "Rasmus W. Licht received research grants, consulting fees and honoraria within the last three years from Astra-Zeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen Cilag, Sanofi-Adventis.", "Hans-Jurgen Muller received grant/research support, consulting fees and honoraria within the last years from AstraZeneca, Bristol-Myers Squibb, Eisai, Eli Lilly, GlaxoSmithKline, Janssen Cilag, Lundbeck, Merck, Novartis, Organon, Pfizer, Sanofi-Aventis, Sepracor, Servier, and Wyeth." ]